IDEX Free cash flow decreased by 54.7% to $86.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 5.9%, from $91.40M to $86.00M. Over 4 years (FY 2021 to FY 2025), Free cash flow shows an upward trend with a 5.8% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase suggests improved operational efficiency or reduced capital intensity, providing more flexibility for capital allocation. A decrease may indicate higher investment in R&D or infrastructure, or potential challenges in converting earnings into cash.
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and m...
Large-cap medical device and pharmaceutical peers typically maintain strong, positive free cash flow, though levels vary based on the intensity of R&D spending and the lifecycle stage of major product lines.
free_cash_flow| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $120.30M | $141.70M | $135.90M | $63.60M | $96.70M | $181.80M | $147.30M | $121.30M | $119.60M | $206.50M | $179.40M | $136.60M | $117.70M | $191.60M | $157.10M | $91.40M | $146.90M | $188.70M | $189.80M | $86.00M |
| QoQ Change | — | +17.8% | -4.1% | -53.2% | +52.0% | +88.0% | -19.0% | -17.7% | -1.4% | +72.7% | -13.1% | -23.9% | -13.8% | +62.8% | -18.0% | -41.8% | +60.7% | +28.5% | +0.6% | -54.7% |
| YoY Change | — | — | — | — | -19.6% | +28.3% | +8.4% | +90.7% | +23.7% | +13.6% | +21.8% | +12.6% | -1.6% | -7.2% | -12.4% | -33.1% | +24.8% | -1.5% | +20.8% | -5.9% |